Met Life Investment Management, LLC Entrada Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 16,329 shares of TRDA stock, worth $113,813. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,329
Previous 16,329
-0.0%
Holding current value
$113,813
Previous $282,000
47.87%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TRDA
# of Institutions
112Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$33.9 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$30.7 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$30.5 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$19.1 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$14.8 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $219M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...